

NOVO NORDISK A S
Form 6-K
January 14, 2014
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
January 13, 2014
NOVO NORDISK A/S (Exact name of Registrant as specified in its charter)
Novo Allé DK- 2880, Bagsvaerd Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-I
Form 20-F [X] Form 40-F []
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes [] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82



With the transactions stated above, Novo Nordisk owns a total of 104,692,025 treasury shares, corresponding to 3.8% of the share capital. The total amount of shares in the company is 2,750,000,000 including treasury shares.

Novo Nordisk A/S Novo Allé Telephone: CVR no: Investor Relations 2880 Bagsværd +45 4444 8888 24 25 67 90 Denmark Internet: www.novonordisk.com Company announcement No 2 / 2014



amhg@novonordisk.com Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com Investors: Kasper Roseeuw Poulsen

+45 3079 4303

krop@novonordisk.com

Novo Nordisk A/S Novo Allé Telephone: CVR no: Investor Relations 2880 Bagsværd +45 4444 8888 24 25 67 90

Denmark Internet: www.novonordisk.com Company announcement No 2 / 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: January 13, 2014

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer